There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Atara Biotherapeutics (ATRA) and Edwards Lifesciences (EW) with bullish sentiments.
Atara Biotherapeutics (ATRA)
In a report issued on November 29, Phil Nadeau from Cowen & Co. reiterated a Buy rating on Atara Biotherapeutics. The company’s shares closed yesterday at $39.95.
According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 6.7% and a 49.6% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Rocket Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Atara Biotherapeutics with a $44 average price target.
See today’s analyst top recommended stocks >>
Edwards Lifesciences (EW)
In a report released yesterday, Josh Jennings from Cowen & Co. maintained a Buy rating on Edwards Lifesciences, with a price target of $190. The company’s shares closed yesterday at $162.01.
According to TipRanks.com, Jennings is a 3-star analyst with an average return of 2.7% and a 58.8% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Baxter International, and Stryker Corporation.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Edwards Lifesciences with a $163.33 average price target, which is a 0.8% upside from current levels. In a report issued on November 16, Wells Fargo also maintained a Buy rating on the stock with a $172 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
